pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Wainua
drug · oligonucleotide
save

eplontersen sodium

Marketedupdated 6mo ago
by $AZN ASTRAZENECA PLC🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval20 co-mentions · 5 sources
  • drugWAINUA (AUTOINJECTOR)20 co-mentions · 5 sources

Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for familial amyloid neuropathy and polyneuropathy and 1 investigational indication.

targets

Transthyretin mRNA

all catalysts(5)

approval · 5
Dec 21, 2023
approval
$AZN185.48-0.69%
3y ago
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Sep 25, 2024
approval
$AZN185.48-0.69%
2y ago
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Apr 18, 2025
approval
$AZN185.48-0.69%
2y ago
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Dec 17, 2025
approval
$AZN185.48-0.69%
11mo ago
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Apr 15, 2026
approval
$AZN185.48-0.69%
7mo ago
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 21, 2028
~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

  • Aug 25, 2034compositionUS 10683499
  • May 1, 2034compositionUS 9127276
  • May 1, 2034compositionUS 9181549
  • Apr 1, 2026compositionUS 8101743

FDA exclusivities (2)

  • Dec 21, 2030ODE-461Orphan Drug (7y)4.1y
  • Dec 21, 2028NCENew Chemical Entity (5y)2.1y

News(10)

  • AstraZeneca’s bruising summer raises the stakes for 2027
    When one of AstraZeneca’s medicines, Wainua, failed a major late-stage heart disease trial in July, it was a jarring setback for a drugmaker whose research pipeline had become one of the most admir…
    endpoints · 14d ago
  • GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatment
    Hibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis Pharmaceuticals’ antisense platform, which has already generated two other new drug ap…
    biospace · 21d ago
  • Alnylam bulls and bears fight it out after business-shaking guidance cut
    While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.
    biospace · 23d ago
  • AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
    AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in…
    biospace · 27d ago
  • Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
    Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic…
    biospace · 1mo ago
  • 5 biotechs braving the commercial waters with product launches
    A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.
    biospace · 1mo ago
  • Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
    After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile…
    biospace · 2mo ago
  • Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
    Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbrea…
    biospace · 2mo ago
  • STAT+: Trump strikes nine more deals with drugmakers to lower prices
    President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.
    stat · 2mo ago
  • ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
    As AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua, several analysts contend it’s too early to count out Alnylam’s silencing dr…
    fiercebiotech · 2mo ago
view all news mentions →
brand
Wainua
trade names
Wainua, Wainua (autoinjector)
generic
eplontersen sodium
MOA
Transthyretin mRNA antisense inhibitor
indication
Familial Amyloid Cardiomyopathy
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?